Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?
Cardiovascular Diabetology, August 2018
Alexander Tenenbaum, Enrique Z. Fisman
There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake. Even so, almost all endpoints in the so-called "negative" meta-analyses leaned toward a trend for benefit with a near 10% reduction in cardiovascular outcomes and a borderline statistical significance. Many trials included in these meta-analyses tested an insufficient daily dose of omega-3 PUFA of less than 1000 mg. Probably, the consistent cardiovascular effects of omega-3 PUFA supplements could be expected only with daily doses above 2000 mg.
|Members of the public||16||89%|
|Practitioners (doctors, other healthcare professionals)||2||11%|
|Readers by professional status||Count||As %|
|Student > Master||5||12%|
|Student > Ph. D. Student||4||10%|
|Student > Doctoral Student||4||10%|
|Readers by discipline||Count||As %|
|Nursing and Health Professions||6||15%|
|Medicine and Dentistry||5||12%|
|Agricultural and Biological Sciences||4||10%|
|Pharmacology, Toxicology and Pharmaceutical Science||2||5%|
|Immunology and Microbiology||2||5%|